

# Mohamed Salah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6958018/publications.pdf>

Version: 2024-02-01

14  
papers

164  
citations

1040056

9  
h-index

1125743

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

199  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/ $\beta$ -synuclein aggregation inhibitors with neuroprotective effects. <i>European Journal of Medicinal Chemistry</i> , 2022, 227, 113911.	5.5	11
2	Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4302-4318.	3.5	4
3	Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis. <i>Biochemical Pharmacology</i> , 2020, 172, 113781.	4.4	10
4	Design, Synthesis, and Biological Characterization of Orally Active 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7289-7301.	6.4	7
5	Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17 $\beta$ -Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 93-107.	5.5	6
6	Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1362-1372.	6.4	5
7	Inhibitors of 17 $\beta$ -hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges. <i>Molecular and Cellular Endocrinology</i> , 2019, 489, 66-81.	3.2	24
8	Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 270-285.	5.5	16
9	Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core. <i>MedChemComm</i> , 2018, 9, 1045-1053.	3.4	10
10	Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1031-1050.	5.5	18
11	First Dual Inhibitors of Steroid Sulfatase (STS) and 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 (17 $\beta$ -HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4086-4092.	6.4	23
12	Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17 $\beta$ -HSD1 inhibitor with sub-nanomolar IC <sub>50</sub> for a proof-of-principle study. <i>European Journal of Medicinal Chemistry</i> , 2017, 127, 944-957.	5.5	15
13	Synthesis and Optimization of New 3,6-Disubstituted indole Derivatives and Their Evaluation as Anticancer Agents Targeting the MDM2/MDM1 Complex. <i>Chemical and Pharmaceutical Bulletin</i> , 2016, 64, 34-41.	1.3	3
14	First Structure-Activity Relationship of 17 $\beta$ -Hydroxysteroid Dehydrogenase Type 14 Nonsteroidal Inhibitors and Crystal Structures in Complex with the Enzyme. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 10719-10737.	6.4	12